CSGCT Park Tour Debut at J.P. Morgan Healthcare Conference 2025 Successfully Concludes in San Francisco

VBI Investment Incubator Business Partner andMs. Gao Yinghong, Vice President of Business Development at Viva Biotech

The first topic is《MNC Partnering with China: looking back on 2024 and forward to 2025》at the roundtable discussion,Ms. Huang Danjie, Vice President of Bayer’s Prescription Drug Division and Head of the China Collaboration and Innovation Center; Dr. Zheng Jing, Co-founder and CEO of Belief BioMed; Dr. Huang Luping, Chief Business Officer of Fucheng Capital; and Venture Partner at VBI (Viva Biotech Incubator) and ViGao Yinghong, Vice President of BD at YashengwuMs.Guest Speaker，Dr. Bao Chaolemeng, Partner at Meibo Capital / Managing Director of Qixing PharmaServed as the moderator of the roundtable discussion. This session focused on collaborations between multinational pharmaceutical companies and Chinese enterprises. Panelists shared their experiences and challenges from diverse perspectives, including those of multinational pharma firms, Chinese biotechnology companies, industry investors, and incubators. They engaged in in-depth discussions on source innovation, product optimization, and balancing R&D capabilities with market demands. Regardless of corporate strategy, companies must always remain patient-centric and committed to value creation. Furthermore, international cooperation should not be expected to yield immediate results; long-term partnerships require a gradual, sustained approach.

Roundtable Discussion 1

Guest Perspective: Whether pursuing a NewCo structure or a licensing deal, do not focus solely on financial figures; identifying the right partner is more critical. To successfully close a project, you must craft a compelling narrative that resonates with the seller. Even when both parties share a strong relationship, this does not guarantee agreement on terms, as each side represents distinct interests and requires ongoing communication to mutually understand each other’s demands. Do not use ChatGPT to replace lawyers in reviewing legal issues.

Roundtable Discussion 2

【CSGCT】 The Innovation of Chinese CGT Biotech

Guest Perspective: China’s CGT industry is gaining momentum, advancing in lockstep with Europe and the United States. During this year’s JPM Week, numerous Chinese CGT companies engaged in exchanges to seek opportunities for NewCo formations and business development (BD), underscoring that global expansion has become a shared strategic imperative for the industry. On a global scale, nationality-based considerations regarding asset origins are gradually fading. Instead, robust intellectual property (IP), solid clinical data, and strong CMC capabilities have become key determinants of successful internationalization. Furthermore, maintaining an open mindset and adopting flexible strategies—such as exploring the NewCo model—is advisable for all biotech companies to understand and consider.

During the roadshow session of this event, four companies with core competencies and a global perspective were invited to deliver presentations. Each company shared insights on their corporate development and explored opportunities for international collaboration.

With this, the event was successfully concluded!Just like the weather in San Francisco during this J.P. Morgan Conference, the industry’s development in 2025 is filled with warmth and hope. Let us embark together on a new journey of international cooperation for China’s pharmaceutical industry!

Meibo Capital(MybioCapital)，As a top-tier pharmaceutical BD investment banking service provider in China, we specialize in asset transactions and international collaborations for Chinese pharmaceutical companies. Our team consists of senior partners from the United States, Europe, the Middle East, Japan, Southeast Asia, and China, who possess scarce core resources in their respective regions and work collaboratively to deliver professional BD consulting and investment banking services. For BD collaboration inquiries, please contact: Mike Liu (Wen Zheng), WeChat: lwzmike, Email: mike.liu@mybiobd.com

VCBeat New MedicineAs a media research platform under VCBeat focusing on biomedicine, it provides innovators and entrepreneurs with communication value characterized by “depth” and “incremental growth” through two dimensions: content and operations. In terms of content, key offerings include exclusive coverage of financing rounds, corporate interviews, thematic features on specific sectors, in-depth industry analyses, and sector reports.etc.; in terms of operations, through branded programs such as “Park Tours” and “VB Think Tank Sessions,” we focus on practical issues, discuss industry trends, and foster actual collaboration through the exchange of ideas.

CoJourneyA professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA production, preparation, and analytical testing. It has successful experience in submitting Investigational New Drug (IND) applications for plasmids and viral vectors in China and the United States with zero deficiency letters. It provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.Xingcheng Biopharma was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy sector, alongside accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP-compliant manufacturing facilities for plasmids, viral vectors, and mRNA that adhere to FDA, EU, and NMPA regulations. Equipped with advanced production and analytical instrumentation, our team brings extensive process development expertise and practical industry experience. Guided by the philosophy of “Acting with Utmost Sincerity,” we leverage robust processes that exceed industry standards to deliver high-purity, high-yield, and cost-effective services to our partners, supporting scalable production of plasmids, viral vectors, and mRNA from R&D through to GMP-grade manufacturing.

Shanghai Lepure Biotechnology Co., Ltd.Established in 2011, the company has pursued an inorganic growth strategy by integrating outstanding brands such as Gries Fluid, Kangsheng Biotech, and Stanleys. Its business scope now covers multiple application scenarios, including cell culture, filtration and purification, single-use systems, and industrial-grade contamination-controlled clean solutions. It has become a widely recognized leading supplier providing end-to-end upstream biopharmaceutical processing solutions.Mission and Vision: Driven by technological innovation, we provide high-quality bioprocessing solutions and are committed to becoming the most trusted partner for global biopharmaceutical companies.

Baker McKenzieBaker McKenzie is a globally leading international law firm, founded in 1949 and headquartered in Chicago, United States. The firm operates more than 70 offices across 46 countries and regions, employing approximately 13,000 professionals, including numerous renowned lawyers. Baker McKenzie is distinguished by its extensive experience and exceptional capabilities in cross-border legal services, providing comprehensive legal solutions to multinational corporations, government agencies, and individual clients. Its practice areas span mergers and acquisitions, tax, dispute resolution, intellectual property, labor law, energy, and infrastructure, among others. By combining a global perspective with localized practice, the firm offers clients a unique competitive advantage in navigating complex international legal challenges.‍‍

BCD TravelEstablished for 10 years, we provide exceptional air ticketing services to B2B enterprises and individual consumers. We partner with over 2,000 airports, with flight routes covering more than 160 countries and regions, particularly boasting mature advantages in Sino-U.S. business travel. Our offerings include:

· Clear Service Process: Customer provides travel requirements — Provide at least four flight options — Customer selects the option with the best price-to-quality ratio — Explain refund, change, and endorsement policies, as well as potential travel risks — Customer makes final decision after full understanding — Ticket issuance — Pre-departure reminder to ensure all boarding documents are prepared — Smooth departure and after-sales service.

· One-sentence summary: Reasonable airfare, clear refund and change policies, one-on-one human communication and travel consultation (always reaching a real person, not a bot), asand emergency handling of other unforeseen circumstances, ensuring you a worry-free and comfortable travel experience.

For inquiries, please scan the QR code below: